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1. Introduction 
During the treatment for acute leukemia (AL) a patient may experience a wide variety of 
complications that mainly have three possible origins, namely the disease itself (leukemic 
infiltration), peripheral blood cell depression (because of hemorrhagic or infectious 
processes) and toxicity induced by chemotherapy. 
The toxicity of chemotherapy is a common cause of morbidity and mortality in cancer 
patients, as well as a frequent source of sequelae at mid-long term. These adverse effects are 
often the consequence of direct toxicity in healthy tissue, as a result of the low specificity 
displayed by these drugs. Furthermore, and regardless of their specificity, these compounds 
may also exacerbate complications derived from the tumor growth, as it is the case of 
pancytopenia or the Tumor Lysis Syndrome. Chemotherapy toxicity becomes more frequent 
as the treatment is intensified, thus challenging the clinician with both diagnostic and 
therapeutic problems. In this chapter we will discuss the major clinical signs of toxicity 
produced by chemotherapy drugs in patients with AL. Hematological and gastrointestinal 
(mucositis, nausea and vomiting) adverse effects will not be included, as their description 
suits better in an Initial Management chapter. In the last section of this chapter we will 
discuss recent data on whether pharmacogenetics may help individualize the therapy for 
AL, thus avoiding serious toxicity. 
2. Cardiotoxicity 
Cardiovascular abnormalities in patients with AL usually result from derangements in 
metabolic, electrolyte, and pulmonary function. Because leukemic infiltration of the heart is 
rare, the majority of cardiovascular problems in AL patients are chemotherapy-related 
toxicities produce by anthracyclines (Pihan, 2009). 
Anthracycline chemotherapy is associated with acute effects (occurring during and shortly 
after administration), e.g. electrocardiographic alterations including prolongation of QT 
interval, development of ventricular late potentials and various arrhythmias (Bagnes et al., 
2010); subacute effects (noted within days or weeks of administration) consisting of toxic 
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myocarditis or pericartitis and chronic effects, which occur weeks or months after 
administration and manifest as cardiomyopathy. Cardiomyopathy is a multifactorial 
process related to oxidative stress and myocyte induction of apoptosis. Our inability to 
predict and prevent anthracycline cardiotoxicity is, in part, due to the fact that the molecular 
and cellular mechanisms remain controversial and incompletely understood (Sawyer et al., 
2010). 
At a cumulative dose of 550 mg/m2 doxorubicin more than a quarter of patients develop 
congestive heart failure (CHF). This complication can take place at lower doses in 
susceptible individuals such as elderly, children, subjects with prior cardiac disease, and 
those who have had previous mediastinal irradiation (Ng et al., 2006). In the pediatric 
population , cardiomyopaty can occur at cumulative doses of 300 mg/m2 (given as 
daunorubicin equivalent) (Creutzig et al., 2007). In addition, the long-term effects of cardiac 
damage are more apparent in children. In a study of long term survivors of childhood 
cancers, cardiac mortality was shown to be the second most likely cause of death following 
malignancy (Creutzig et al., 2007). 
There are different techniques utilized to monitor for cardiotoxicity: 
1. Endomyocardial Biopsy (EB), which was traditionally viewed as the gold standard test, 
is actually an impractical means of monitoring due to the invasive nature of test. 
2. Evaluation of left ventricular ejection fraction (LVEF) with two-dimensional 
echocardiography (2D-ECHO) or radionuclide ventriculography remains the most 
pragmatic monitoring technique. Calculation of the LVEF by 2D-ECHO is slightly more 
difficult; however, the fact that radiation is not used makes it more suitable for the 
pediatric population. 
3. Other techniques have also been tested: Antimyosin antibody scintigraphy is a marker 
of cardiac damage, but its high sensitivity may produce positive results at very low 
cumulative doses of anthraciclines, thus limiting its clinical utility (Valdes Olmos et al., 
2002). Cardiac troponins and natriuretic peptides, the most commonly used biomarkers 
of myocardial destruction and ventricular dysfunction respectively, have also been 
studied for this purpose (Germanakis et al., 2008). 
Pretherapy baseline evaluation of LVEF is recommended for all patients with AL before 
starting induction therapy. However, unless the patient is known or suspected to have a 
cardiac disease, the treatment does not need to be delayed pending the results of LVEF 
(Pihan, 2009). Dose exposure should be reduced in patients with a baseline LVEF of less 
than 50% or in those with a 10% LVEF decline from baseline to final values below 50% 
(Schwartz et al., 1987). 
Different anthracyclines have different patterns of toxicity (Table 1). However, changing to a 
different anthracyclin does not substantially modify the risk for cardiotoxicity. In an attempt 
to reduce this adverse effect, liposomal doxorubicin has been developed. Most studies with 
liposomal doxorubicin have been performed in women with metastatic breast cancer. In this 
population, liposomal doxorubicin has shown equivalent efficacy to doxorubicin with a 
reduced rate of cardiotoxicity (Batist et al., 2001). 
Several meta-analysis have studied the influence of different anthracyclines or different 
dosage schedules on the risk of cardiotoxicity in adult patients with cancer. These studies 
support the administration of a 6-hour (or longer) infusion (van Dalen et al., 2009), and the 
use of liposomal-doxorubicin over doxorubicin (van Dalen et al., 2010). It is of note that both 
studies agree in that there is insufficient evidence to implement such measures in children 
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or in patients with leukemia. In this regard, a meta-analysis with data retrieved from trials 
in children with ALL that randomized anthracyclines or measures to reduce cardiotoxicity, 
found no significant differences regarding type of anthracycline, method of administration 
or use of cardioprotectants (Childhood ALL Collaborative Group, 2009). 
Because one of the proposed mechanisms of anthracyclins cardiotoxicity involves the 
generation of free iron radicals, dexazoxane, by its iron chelating effect, confers a significant 
reduction in the risk of cardiotoxicity. A meta-analysis by Van Dalen et al concluded that if 
the risk of cardiac damage is expected to be high, it might be justified the use of 
dexrazoxane in patients with cancer treated with anthracyclines (van Dalen et al., 2008). In 
children with AL, the use of dexrazoxane seems safe and provides long-term 
cardioprotection without compromising oncological efficacy. Currently, in the absence of 
more data, the use of dexrazoxane might be justified in children if the risk of cardiac 
damage is expected to be high (Lipshultz et al., 2010). 
2.1 Treatment of cardiomyopathy 
The natural history of Anthracyclines cardiomyopathy, as well as its response to modern 
CHF therapy, remains poorly defined. Hence, evidence-based recommendations for the 
management of this form of cardiomyopathy are still lacking. Progress in treatment of 
cardiac failure, in particular the availability of drugs as angiotensin converting enzyme 
(ACE) inhibitors, spironolactone and beta-blokers and the current practice of monitoring 
cardiotoxicity, may explain the improved prognosis of this complication that , in early 
retrospective studies ,  had a mortality rate of more than 40%. The prophylactic use of 
enalapril resulted in the reduction of cardiac function deterioration. A recent study has 
shown that when this therapy is initiated soon after detection of LVEF impairment, there are 
more patients who present LVEF recovery and cardiac event reduction (Cardinale et al., 
2010). These results show the importance of monitoring cardiotoxicity in all patients treated 
with anthracyclines in order to (i) identify early heart damage and (ii) begin treatment 
before the onset of CHF.  
Among the newest compounds, symptomatic or asymptomatic QT aberrations have been 
reported with tyrosine-kinase inhibitors (Bagnes et al., 2010) and arsenic trioxide (Ohnishi et 
al., 2000). 
 
Adverse effect CTX MTX ADR DNR EPI IDA NOV AMS 
         
Cardiomyopathy   +++ +++ ++ ++ ++ + 
Myo/pericarditis ++  + ++ +    
ECG changes ++ + ++ ++    + 
 
CTX, cyclophosphamide; MTX, methotrexate; ADR, doxorubicin; DNR, daunorubicin; EPI, epirubicin;  IDA, 
idarubicin; NOV, mitoxantrone; AMS, amsacrine. 
 +, rare or little clinical significance; ++, occasional or clinically relevant; +++, common or severe. 
Table 1. Main cardiac toxicity for chemotherapy drugs used in acute leukemia 
3. Hepatotoxicity 
Hepatotoxicity is defined as an injury to the liver that is associated with impaired liver 
function caused by exposure to a drug. The clinical patterns of liver injury are defined as 
hepatocellular, with a predominant initial elevation of the alanine aminotransferase level 
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(ALT), cholestatic, in which the serum alkaline phosphatase concentrations are increased, or 
mixed, if both enzymes are elevated. An ALT level of more than three times the upper limit 
of normal values and a total bilirubin concentration of more than twice the upper limit are 
used to define clinically significant abnormalities on liver test. Elevation in serum enzyme 
levels is taken as indicator of liver injury, whereas increases in bilirrubin levels, albumin 
concentration and the prothrombin time are measures of overall liver function (Navarro & 
Senior, 2006). 
Chemotherapy-induced hepatotoxicity is a common cause of abnormal liver function test in 
patients with AL. It mainly occurs in an idiosyncratic manner and is generally reversible 
and nonfatal. This toxicity is manifested in a variety of patterns. In addition to those 
mentioned above, we find steatosis, ductal injury fibrosis, cirrhosis, veno-occlusion, peliosis 
hepatis, and nodular regenerative hyperplasia. The two latter lesions appear as 
pseudometastatic hepatic nodules that may indicate disease progression, especially if they 
are multiple (Brisse et al., 2000). 
Hepatotoxicity usually begins with vague clinical symptoms such as fatigue, anorexia, 
nausea, dark urine, right upper quadrant discomfort and jaundice. Suspected drug exposure 
must precede the symptoms and liver injury may improve when administration is stopped. 
However, the latent period is highly variable and enzyme levels may take weeks to increase. 
Before attributing these symptoms to a chemotherapy drug, other causes of liver injury must 
be ruled out (Navarro & Senior, 2006). Abnormal liver function may be due to multiple 
causes in patients with AL. Leukemic infiltration usually causes mild to moderate 
hepatomegaly with limited impact on serum transaminase levels. Transfusions increase the 
likelihood of viral hepatitis. Other circumstances such as sepsis, hypotension or 
malnutrition may contribute to liver damage (Pihan, 2009). 
AL patients are treated with combination chemotherapy, making it difficult to identify the 
precise agent involved in the hepatic injury. Moreover, diagnosis becomes more challenging 
by the large number of non-chemotherapeutic drugs commonly used in those patients, some 
of them holding the potential of being hepatoxic, e.g. allopurinol, ondansetron and different 
antifungal agents (Perry, 1992). 
Pre-existing liver disease can alter the metabolism and excretion of chemotherapy causing 
increased and persistent drug levels and hence systemic toxicity. On the other hand, 
chemotherapy may worsen liver disease, such as occurs with hepatitis. Severe liver 
dysfunction and fatal fulminant hepatitis through virus reactivation have been described in 
patients with viral hepatitis. Prophylactic therapy with nucleoside analogues, typically 
lamivudine, has been recommended for HBs Ag positive patients. This strategy has been 
reported to allow optimal administration of chemotherapy (Parrish et al., 2010). 
3.1 Dose modification of chemotherapy with altered hepatic function 
All patients with AL must undergo evaluation of baseline values before starting 
chemotherapy. This includes liver function test, viral hepatitis serology and, if clinically 
indicated, hepatic imaging. Liver function test should be reassessed before each course of 
therapy and known hepatotoxins should be avoided (Perry, 1992). Patients more susceptible 
to hepatotoxicity such as those with malnutrition or alcoholism, elderly, obese, or diabetic, 
should be followed up more closely. Liver response may also be abnormal in cases of 
previous liver disease or coexisting illnesses (Floyd et al., 2006). In cases of elevated liver test 
(ELT), drugs undergoing hepatic metabolism should be avoided if possible and/or dose 
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modifications should be considered if guidelines are available. In rare instances in which 
ELT is caused by leukemic infiltration it is not necessary to adjust dosing (Figure 1). 
 
 
Fig. 1. Liver biopsy of a child with relapsed ALL. Lymphoblasts (C43+) infiltrate the hepatic 
sinusoids. Despite of abnormal liver test, chemotherapy was administered without 
complications. 
3.2 Hepatotoxicity of major chemotherapy agents used in acute leukemia 
3.2.1 6-Mercaptopurine and 6-Thioguanine 
6-Mercaptopurine (6-MP) in orally daily regimen associated with weekly MTX is the 
backbone of maintenance chemotherapy acute lymphoblastic leukemia (ALL). 
Hepatotoxicity produced by this drug include both cholestatic and hepatocellular disease. 
Characteristic diagnostic profiles include prominently elevated serum bilirubin, typically 
between 3 and 7 mg/dL, accompanied by mild to moderate elevations in aminotransferases 
and alkaline phosphatase (Floyd et al., 2006). Liver function tests are transiently abnormal in 
the majority of children during maintenance of ALL, in the absence of other evidence of 
severe liver toxicity or viral hepatitis, it is generally not necessary to withhold or reduce the 
dose of continuation chemotherapy (Pui & Evans, 2006). When liver biopsies are performed 
in this population, inflammatory and fatty changes are common and not related with ALT 
levels. Early portal fibrosis is found only in patients with prolonged therapy. The risk of 
portal fibrosis is low after 2-3 years of continuing chemotherapy and most patients go back 
to normal ALT values with drug cessation. The mechanism underlying 6-MP-induced 
hepatotoxicity is related to its methylated metabolites and correlates with ALT levels. 
Indeed, ALT levels have been proposed as a surrogate marker for treatment compliance 
(Nygaard et al., 2004). A study by Schmiegelow et al. has shown that ALL pediatric patients 
with mean ALT levels above the upper normal limit (40 IU/l) who were kept on therapy 
had a significantly lower risk of hematological relapse compared to other children 
(Schmiegelow, 1991). These data support the concept of treating to toxicity for maintenance 
therapy. 
6-Thioguanine as maintenance treatment in childhood ALL has also been shown to cause 
hepatic veno-occlusive disease (VOD) usually mild and reversible on withdrawing 6-TG or 
replacing it with 6-MP (Stoneham et al., 2003). 
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3.2.2 Methotrexate 
MTX inhibits dihydrofolate reductase resulting in depletion of critical reduced folates. The 
net result is effective inhibition of DNA and RNA synthesis and potent cytotoxicity to 
rapidly dividing cells. MTX causes hepatotoxicity, fibrosis and cirrhosis, but usually after 
prolonged use and/or when it is used in the treatment of autoimmune diseases. 
In a high percentage of patients with ALL, MTX causes isolated elevations of ALT during 
maintenance chemotherapy, usually transient and asymptomatic. This ALT elevations are 
not predictive of subsequent hepatic disease and do not require treatment modification 
(Farrow et al., 1997). 
As in the maintenance treatment, when MTX is used in high IV doses (HD-IV MTX), the 
characteristic hepatotoxic pattern is transient, ALT levels are related to the dose of MTX and 
increase with the number of cycles received. A difference with the maintenance treatment is 
that in cases of altered hepatic function it is necessary to modify or suspend the 
administration of HD-IV MTX (Table 2). In any case, despite the usual benign character of 
MTX-induced hepatotoxicity, there are reports of hepatoma in association with hepatic 
fibrosis occurring in children following ALL treatment (Fried et al., 1987). 
3.2.3 Cytarabine 
Cytarabine (ara-C) have revealed a cumulative dose-dependent hepatotoxicity. Several case 
reports have demonstrated direct histologic evidence of a hepatotoxic role for ara-C, 
expressed as increased ALT levels or as intrahepatic cholestasis. Although the actual 
incidence of this toxicity remains to be elucidated, mild elevations of liver function in a 
cholestatic pattern represent the reversible, rarely fatal clinical picture (George et al., 1984). 
Ara-C is reported to be partially detoxified in the liver. Therefore, it is recommended that its 
dose be reduced in patients with liver impairment (Table 2). 
3.2.4 L-Asparaginase 
In addition to hypersensitivity reactions, the most common toxic effects of L-asparaginase 
are related to the depletion of proteins synthesized in the liver, such as clotting factor, 
insulin , albumin, haptoglobin and transferrin. Liver function abnormalities (including 
hyperbilirubinemia and elevated transaminase levels) and hyperlipidemia 
(hypertriglyceridemia and hypercholesterolemia) have been frequently reported in patients 
receiving the drug (Earl, 2009). As a result of these metabolic abnormalities, up to 7% of 
children with AL develop pancreatitis (Treepongkaruna et al., 2009). Another common 
metabolic complication of this drug is hyperglycemia, which occurs in up to 10% of children 
with AL during their induction therapy (Pui et al., 1981) and is associated with the 
synergistic effect of L-asparaginase and glucocorticoids (Spinola-Castro et al., 2009). It 
should be noted that the use of pegylated asparaginase does not prevent these complications 
(Silverman et al.). 
3.2.5 Other drugs 
In spite of requiring metabolic activation in the liver, cyclophosphamide, antitumor antibiotics 
and vinca alkaloids are uncommon hepatic toxins. Indeed, reports of severe hepatotoxicity 
attributed to these drugs are scarce (Floyd et al., 2006). However, dose modifications are 
necessary to prevent systemic toxicity in case of liver impairment (Table 2). 
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Agent Bilirubin (mg/dl) Aminotransferases % Dose administered 
Alkylating agents
Cyclophosphamide 3.1-5 >3 x ULN 75
>5 0
Antimetabolites
Cytarabine Any 50%; increase by 
monitoring toxicity 
6-mercaptopurine No dose reduction 
is necessary 
Methotrexate 3.1-5.0 >3 x ULN 75
>5.0 0
6-Thioguanine >5.0 0
Antibiotics 
Doxorubicin 2-3 x ULN 75
1.2-3.0 >3 x ULN 50
3.1-5.0 25
>5.0 0
Daunorubicin 1.2-3.0 75
3.1-5.0 50
>5.0 0
Epirubicin 1.2-3 2-4 x ULN 75
>3 >4 xULN 50
Idarubicin 1.5-3.0 AST 2-3 x ULN 75
3.1-5.0 AST>3 x ULN 50
>5 0
Mitoxantrone >3.0 75
Plant alkaloids 
Vincristine and 
Vinblastine* 
1.5-3.0 2-3 x ULN 50
>3.1 >3  x ULN 0
Etoposide 1.5-3.0 AST>3 x ULN 50
>3 AST>3 x ULN 0
Teniposide Evaluate if necessary 
Miscellaneous 
L-asparaginase No dose reduction 
is necessary 
*Vincristine and vinblastine: 50% reduction if alkaline phosphatase is elevated. ULN, Upper limit of normal. 
Table 2. Dosage of main chemotherapeutic agents used in AL according to liver function 
4. Peripheral neuropathy 
The most prevalent neurologic complication of cancer treatment is chemotherapy-induced 
peripheral neuropathy (CIPN). Vincristine is the main etiological agent involved in 
peripheral neuropathy in leukemia patients (Kannarkat et al., 2007). Virtually all ALL 
patients receiving vincristine have some degree of neuropathy. Neurotoxicity commonly 
pesents as peripheral neuropathy, which is predominantly sensory in nature. The clinical 
manifestations are subjective and predominantly manifest as distal and symmetrically 
distributed pure sensory symptoms such as paresthesias, hyperesthesias, hypoesthesias, and 
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dysesthesias. The most common and earliest symptoms are numbness and tingling in the 
fingertips and feet as well as constipation due to autonomic neuropathy. Symptoms of 
motor weakness are observed in patients with more persistent and severe sensory findings. 
Isolated motor weakness with the complete absence of sensory involvement has not been 
reported. If such findings were observed, consideration should be given to other conditions 
such as steroid myopathy  or diabetic neuropathy (Hausheer et al., 2006). 
Sensory findings, as diminished or absent proprioception and vibration are typically 
diminished in the stocking-glove distribution in symptomatic patients. Loss of ankle stretch 
reflexes is an early and almost universal sign, and with continued therapy all reflexes may 
diminish or disappear. The toxicity of vincristine is believed to occur through disruption of 
microtubule polymerization. Neurophysiologic studies are compatible with a primarily 
axonal neuropathy. Symptoms develop gradually and may manifest after the first dose. As 
the disease progresses, muscle weakness becomes apparent, patients lose the ability to walk 
on their heels and lose strength in wrist extensors. Motor weakness from vincristine can 
become severe enough to render the patient immobile. In addition, some patients may 
develop impotence, postural hypotension, or an atonic bladder (Quasthoff & Hartung, 
2002). When symptoms are severe, a hereditary motor and sensory neuropathy should be 
suspected (Mercuri et al., 1999). 
Because there is no effective treatment, prevention is the only useful measure for 
neurotoxicity. All patients should take prophylactic stool softeners and/or laxatives. Dose 
level and cumulative dose are the most significant risk factors. The maximum dose of 2 mg, 
and cumulative doses over 15-20 mg should not be exceeded due to the considerable 
increase in the incidence and severity of symptoms. When symptoms of neuropathy disturb 
the patient a common practice is to administer vinblastine instead and even to discontinue 
therapy if marked weakness appears. Recovery generally occurs 1 to 3 months after 
treatment cessation, withholding the drug or reducing its dose, but CIPN symptoms may 
also persist or worsen following vincristine discontinuation (Verstappen et al., 2005). 
5. Central neurotoxicity 
Chemotherapy-induced central neurotoxicity can result in multiple clinical manifestations: 
impaired consciousness, focal deficits, seizures, headaches, etc. However, before attributing 
these symptoms to chemotherapy in AL patients, other causes must be ruled out first (Table 
3). Furthermore, it is necessary to consider other factors such as drug-drug interactions. For 
instance, MTX intracellular levels may be elevated in the presence of vincristine. In addition, 
circumstances such as cranial irradiation or CNS affectation by leukemia may cause direct 
damage to the blood–brain barrier, thereby increasing MTX permeability and subsequent 
toxicity (Naing et al., 2005). 
 
Metabolic disturbances (e.g. hyponatremia) 
Intracerebral hemorrhage 
Cerebral infarction or venous sinus thrombosis 
CNS infection 
Meningeal Leukemia 
Epilepsy 
Migraine 
Drugs 
Table 3. Main causes of CNS disease in patients with AL 
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5.1 Cerebrovascular accidents 
In patients with AL, ischemic or hemorrhagic cerebrovascular accidents may be either a 
consequence of the disease or a complication of chemotherapy. Intracranial hemorrhage 
(ICH), which is the second leading cause of mortality in patients with acute myeloid 
leukemia (AML) (accounting for up to 70% in some series), occurs mostly during induction 
therapy. Brainstem, epidural and subarachnoid hemorrhage are particularly dangerous 
(Chen et al., 2009). In a risk score model for fatal intracranial hemorrhage, female gender, 
thrombocytopenia, prolonged prothrombin time, hyperleukocytosis (particularly in 
presence of symptoms of pulmonary leukostasis), and acute promyelocytic leukemia (APL), 
were significantly associated with the occurrence of this complication (Kim et al., 2006). 
Thrombotic events, particularly sino-venous thrombosis, are more frequent in ALL. Therapy 
with L-asparaginase is considered the major risk factor for this complication in these 
patients. Thrombosis develops after the administration of the first doses of the drug in 
induction therapy. The most common symptoms are headaches and seizures which resolve 
without sequelae in most cases (Kieslich et al., 2003). In a previous study with 238 patients 
treated with L-asparaginase, 4.2% of patients showed cerebral thrombosis and 2.1% cerebral 
haemorrhages (Nicholson et al., 1996). In this regard, it has been shown that increased 
triglycerides and decreases of antithrombin III, fibrinogen, protein S, protein C, 
plasminogen and alpha-2-antiplasmin are associated with the dose of L-asparaginase 
(Hongo et al., 2002; Nowak-Göttl et al., 1994). Other factors such as central venous catheters, 
obesity, use of steroids and thrombophilia may contribute to thrombotic imbalance in these 
patients.  
5.2 Aseptic meningitis 
Aseptic meningitis or chemical arachnoiditis is the most common neurotoxicity induced by 
MTX. It affects approximately 10% of patients receiving intrathecal (IT) therapy. The onset is 
generally abrupt and occurs within hours of IT administration. The patient has headache, 
meningismus, nausea, vomiting, fever, and altered consciousness. Cerebrospinal fluid (CSF) 
studies demonstrate pleocytosis and elevated protein. The symptoms are self-limited and 
usually resolve within 72 hours. Further treatment with IT MTX is not contraindicated and 
patients may receive subsequent doses of chemotherapy without incident. Co-
administration of MTX and IT hydrocortisone or premedication with oral corticosteroids 
may be useful to prevent the syndrome (Sul & Deangelis, 2006). The use of IT ara-C can also 
result in aseptic meningitis similar to that seen with IT MTX. The incidence has been 
observed to be higher with the liposomal formulation (DepoCyt®), which maintains 
cytotoxic concentrations of the drug in the CSF for up to 14 days. Side effects become so 
frequent that all patients require prophylactic corticosteroids pre and post DepoCyt® 
administration (Glantz et al., 1999). 
5.3 Transverse myelopathy 
Transverse myelopathy is an uncommon complication of IT MTX manifested by the 
development of back or leg pain followed by paraplegia, sensory loss, and sphincter 
dysfunction in the absence of a compressive lesion. The onset is usually between 30 minutes 
and 48 hours after treatment, although the reaction may also appear up to two weeks later. 
MRI may illustrate cord edema and irregular post-gadolinium enhancement. In contrast to 
myelopathies caused by other reasons, corticosteroids are not helpful. This is thought to be 
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an idiosyncratic drug reaction, and therefore the identification of potentially susceptible 
patients is not possible. Unlike aseptic meningitis, transverse myelopathy is an absolute 
contraindication to further treatment with IT MTX. In addition to IT MTX, a similar 
transverse myelopathy was reported in two pediatric AML patients receiving IT and IV ara-
C (Sul & Deangelis, 2006). 
5.4 Acute encephalopathy 
High doses of Cytarabine (HD-ara-C) (≥3 g/m2 every 12 hours) may result in CNS 
dysfunction, especially impaired cerebellar function. The characteristic syndrome begins 
with somnolence and occasionally encephalopathy that develops two to five days after 
treatment. Immediately thereafter, cerebellar signs are noted on physical examination. 
Symptoms range in severity from mild ataxia to inability to sit or walk unassisted. Rarely, 
seizures may also develop. There may be MRI changes in the white matter and cerebellum, 
but the CSF is usually normal. Discontinuation of therapy generally results in partial 
recovery within several weeks, but complete resolution is achieved by only 30% of patients. 
Neurologic deficits can be permanent if treatment is continued after the onset of symptoms 
(Friedman & Shetty, 2001). 
Since the occurrence of severe cerebellar dysfunction is greatly affected by age, patients 
older than 50 years should be given a reduced schedule of HD-ara-C. Furthermore, it has 
been shown that avoidance of very high doses of the drug in patients with renal impairment 
and the administration of HD-ara-C on a once-daily rather than twice-daily schedule reduce 
the incidence of this syndrome (Smith et al., 1997). 
5.5 Subacute encephalopathy 
Subacute encephalopathy is an uncommon complication of MTX therapy that generally 
develops within 5–14 days after the administration of IT or HD-MTX, not being observed in 
maintenance therapy when low doses of oral or parenteral MTX are used. The syndrome is 
manifest by abrupt onset of focal neurological deficits, such as aphasia or hemiparesis and 
presents after a median of three courses of IV or IT MTX. Typical symptoms are headache and 
nausea followed by stroke-like hemiparesis or bilateral weakness. Hemiparesis may be 
alternating and evolving over a period of minutes to hours. In addition, aphasia or expressive 
dysphasia, emotional lability and disorientation are also common signs. Other manifestations 
such as seizure, transient ataxia, choreoathetoid movements, temporary blindness or visual 
hallucinations are less frequent. Most neurological symptoms resolve after 1-7 days and the 
majority of patients can resume HD-MTX therapy without permanent neurological sequelae. 
Recurrence may be experienced by 10-56% patients (Inaba et al., 2008).  
In the absence of histopathological data, diagnosis is based upon spinal fluid analysis and 
neuroimaging techniques. CFS analysis is usually normal and electroencephalogram (EEG) 
shows nonspecific diffuse or focal slowing. At the onset of MTX-induced encephalopathy, 
conventional CT scans, T1 or T2 weighted MR imaging and angiography typically show no 
abnormalities, whereas diffusion-weighted imaging (DWI) is able to show restricted 
diffusion of water in the brain that clears after resolution of the clinical symptoms. This 
abnormalities are consistent with cytotoxic or intramyelinic sheath edema within white 
matter tracts (Haykin et al., 2006). Follow-up MR imaging shows variable abnormal T2 and 
FLAIR signal intensity in the deep white matter, with no detectable neurological sequelae in 
most patients (Haykin et al., 2006) (Figure 2). The pathogenesis of MTX neurotoxicity is 
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poorly understood and no specific risk factors for the development of this complication have 
been identified to date. Indeed, pharmacokinetic data are normal in most patients with 
MTX-induced neurotoxicity (Rubnitz et al., 1998). In this regard, there are recent data 
indicating that pharmacogenetics could play a significant role in the development of this 
complication (Mahadeo et al., 2010; Vagace et al., 2011).  
 
 
Fig. 2. MR imaging findings six weeks after an episode of subacute encephalopathy by MTX. 
White arrows in Axial T2 (A) and coronal FLAIR (B) sequences show deep and periventricular 
white matter hyperintensity, especially in the right hemisphere (Vagace et al., 2011). 
5.6 Posterior reversible encephalopathy 
In 1996, Hinchey et al. described a reversible syndrome of headache, altered mental 
functioning, seizures, and loss of vision associated with abnormalities on neuroimaging in 
the posterior regions of the cerebral hemispheres. The syndrome occured in patients who 
had renal insufficiency or hypertension or in those who were immunosuppressed. Although 
not previously recognized as a complication of chemotherapy, Posterior Reversible 
Encephalopathy (PRE) is now considered as one the most common abnormalities leading to 
seizures in children with leukemia (Norman et al., 2007). The patient usually presents with 
headache, altered alertness, confusion, seizures (that may begin focally but usually become 
generalized), vomiting and alterations of visual perception. These visual disturbances are 
nearly always detectable with symptoms such as blurred vision, hemianopia, visual 
hallucinations or cortical blindness. Hypertension and hypomagnesemia are additional 
diagnostic criteria but are not always present (Dicuonzo et al., 2009). 
 
 
Fig. 3. Posterior Reversible Encephalopaty: MR imaging, Coronal T2 FLAIR, of a child with AL 
treated with vincristine that developed headache, hypertension and seizures. Left panel 
shows white matter hyperintensity in both hemispheres. After 18 days (right panel) these 
signs were inappreciable. 
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The cardinal features of PRE are both clinical and radiologic. Abnormalities are usually 
observed in bilateral, parietal and occipital lobes. CT scans typically show posterior cerebral 
white-matter hypodensities. If PRE is suspected, MRI series should be performed, including 
T2, DWI, and FLAIR images for the most accurate diagnosis. MR abnormalities are 
characterized by increased signal on T2-weighted and FLAIR sequences. DWI may appear 
normal or show increased diffusion consistent with vasogenic edema (Shin et al., 2001) (Fig 3). 
Sudden elevations in systemic blood pressure exceeding the autoregulatory capability of the 
brain vasculature, leading to capillary leakage and subsequent vasogenic edema has been 
proposed as the underlying mechanism of PRE. The preferential involvement of the parietal 
and occipital lobes may be due to the observed relative reduction in the sympathetic 
innervation of the posterior circulation. Based on brain SPECT studies, a migraine-like 
mechanism has been proposed by other authors. Additionally, hypomagnesemia or vascular 
instability resulting from the toxicity of the chemotherapy agents on the endothelium of the 
blood-brain barrier may also be contributing factors (Sanchez-Carpintero et al., 2001). Most 
cases of PRE occur during induction chemotherapy for ALL, consequently, a variety of 
drugs routinely used during this phase have been linked to PRE, namely vincristine, IT 
MTX, HD-MTX, L-asparaginase, cyclophosphamide and ara-C (Gupta et al., 2008). 
Early and aggressive therapy for hypertension and quickly control the seizures, are the only 
defined treatment recommendations for this syndrome. In most patients chemotherapy can 
be restarted without recurrence or permanent neurological sequelae. In conclusion, 
chemotherapy for AL should be added to the growing list of causes of PRE. However, more 
information is needed before a clear association can be established between PRE and specific 
chemotherapy agents (Titos-Arcos et al., 2011). 
5.7 Chronic Leukoencephalopaty 
Chronic leukoencephalopathy is a commonly described but poorly understood phenomenon, 
which is associated with the use of HD-MTX with inadequate leucovorin rescue and that 
may be exacerbated by prior cranial irradiation. This complication presents several months 
to years after therapy and may lead to severe neuropsychological impairment (Ziereisen et 
al., 2006). 
6. Renal toxicity and electrolytes imbalance 
The kidneys, being the elimination pathway of many antitumor drugs and their metabolites, 
are quite vulnerable to injury in chemotherapy. Several factors are known to contribute to 
the nephrotoxic potential of antineoplastic drugs in patients with AL, namely the 
concomitant use of other nephrotoxic drugs (e.g., amphothericin), urinary infections, 
intravascular volume depletion, sepsis and other comorbidities such as hypertension, 
diabetes mellitus or heart failure. Suggested dosing of the main chemotherapeutic drugs 
used in AL according to renal function is shown in Table 4. 
Chemotherapy-induced nephrotoxicity may affect glomeruli, tubules, renal vasculature or 
excretory system depending on the drugs involved. Creatinine clearance is the usual measure 
to assess the glomerular filtration rate. Serum creatininine is less sensitive for this purpose and 
does not significantly change until the clearance is below 70 ml/min. Measurement of the 
tubular function is often accomplished by evaluating the fractional excretion of glucose, uric 
acid, calcium, phosphorous and magnesium (de Jonge & Verweij, 2006). 
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6.1 Hemorrhagic cystitis 
Cyclophosphamide and ifosfamide are drugs with similar chemical structures that are 
biotransformed to acrolein. Hemorrhagic cystitis occurs subsequent to urinary excretion of 
this metabolite, which is capable of binding the sulfhydryl constituent within proteins of 
bladder epithelium causing an inflammatory process. Saline-based hyperhydration and 
mesna (2-mercaptoethane sulfonate), which binds acrolein preventing direct contact with 
the uroepithelium, are concurrently administered to reduce the incidence and severity of 
hemorrhagic cystitis. Hemorrhagic cystitis is usually seen in transplant recipients who are 
treated with doses of cyclophosphamide higher than those used in AL. When the process 
lasts longer than 7 days, adenovirus and polyomavirus infection (specifically BK viruria) are 
often responsible (Korkmaz et al., 2007). 
Treatment of hemorrhagic cystitis is challenging. If blood clots form, bladder irrigation with 
isotonic saline may be required to break up an obstructive uropathy. Other measures that 
have been used include intravesical therapy with instillation of chemicals to cause mucosal 
fibrosis, hyperbaric oxygen therapy, and embolization or ligation of internal iliac arteries. 
Cystectomy is reserved for massive bladder hemorrhage, a clinical problem with a high 
mortality rate (Hu et al., 2008). 
 
Agent CrCl (ml/min) [Cr]s (mg/dl) % Dose administered 
Alkylating agents    
Cyclophosphamide 10-50  75 
<10  50 
Antimetabolites    
Cytarabine   Evaluate if necessary 
6-mercaptopurine   No formal recommendation.  
Methotrexate 30-60  50 
<30  0 
Antibiotics*    
Daunorubicin  >3.0 50 
Plant alkaloids    
Etoposide 10-50  75 
<10  50 
Miscellaneous    
L-asparaginase <60  0 
CrCl, creatinine clearance; [Cr]s, serum creatinine 
*No reduction is necessary for mitoxantrone, doxorubicin, epirubicin, idarubicin, vincristine or vinblastine 
Table 4. Dosage of main chemotherapeutic agents used in AL according to renal function 
6.2 Methotrexate-induced nephrotoxicity 
Nephrotoxicity is a potentially life-threatening complication of HD-MTX therapy (>1g/m2). 
Both the parent drug and the 7-hydroxy-MTX metabolite may precipitate in the acidic 
environment of renal tubules and collecting ducts producing acute tubular necrosis. Renal 
dysfunction results in delayed MTX excretion and sustained elevated plasma MTX 
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concentrations, which in turn may lead to a marked enhancement of other toxicities of MTX, 
especially myelosuppression, mucositis, hepatitis, and dermatitis. Uniform institution of 
aggressive hydration, alkalinization (urinary pH monitoring required), and 
pharmacokinetically guided leucovorin rescue , significantly reduce the morbidity rate in 
patients receiving this therapy. Implementation of this regimen reduces the incidence of 
nephrotoxicity to approximately 2% of patients (Widemann & Adamson, 2006). 
Delayed MTX excretion and high plasma MTX concentrations identify patients at high risk 
of toxicity. These subjects may benefit from supplemental leucovorin rescue or from the 
administration of glucarpidase (carboxypeptidase G2, CPDG2), a recombinant enzyme with 
cleaves MTX in inactive metabolites and is able to lower plasma MTX concentrations rapidly 
and efficiently. The use of CPDG2 is well-tolerated and renders a more profound, rapid, and 
consistent decrease in plasma MTX concentrations compared to dialysis-based methods, and 
should therefore be considered over dialysis in patients with HD-MTX-induced renal 
dysfunction (Patterson & Lee, 2010). 
6.3 Syndrome of inappropriate antidiuretic hormone secretion 
Hyponatremia is the most common electrolyte disorder in clinical medicine and occurs in 
approximately one of every three hospitalized patients. The syndrome of inappropriate 
Secrection of Antidiuretic Hormone (SIADH) is the most frequent cause of hyponatremia. 
Malignant diseases, pulmonary and CNS disorders and drugs are causes of SIADH. With 
regard to chemotherapy drugs used in AL, vincristine and cyclophosphamide have been 
implicated in this complication (Ellison & Berl, 2007). 
The diagnosis of SIADH requires the presence of hyponatremia (Na+<135 mmol/L) with a 
low serum osmolarity (<275 mmol/L) in the absence of other causes of hyponatremia such 
as oral or IV water excess, low effective circulating volume (heart or liver failure), use of 
thiazide diuretics, endocrine processes (hipopituitarism, adrenal insufficiency or 
hypothyroidism), renal failure or salt wasting. On the other hand Cerebral Salt Wasting is a 
syndrome due to the production of natriuretic factor and/or a disruption of neural input 
into the kidney that decreases proximal sodium reabsorption, resulting in a loss of sodium 
by the urine. The identification of this disorder is of considerable clinical importance 
because its treatment comprises vigorous sodium and volume replacement, whereas fluid 
restriction is the treatment of choice in SIADH (Hoorn & Zietse, 2008). Table 5 shows useful 
data to differentiate between these two syndromes. 
 
 CSW SIADH 
Extracellular fluid volumen* Decreased Increased 
Diuresis Normal or increased Normal or decreased 
Hematocrit Increased Normal 
Plasma BUN/Creatinine Increased Decreased 
Treatment Normal saline Fluid restriction 
*The main difference but clinical assessment of volume status is imprecise. CSW, cerebral salt wasting; 
SIADH, syndrome of inappropriate antidiuretic hormone secretion. 
Table 5. Clinical features of CSW and SIADH [Modified from (Palmer, 2003)]. 
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7. Pulmonary toxicity 
Most pulmonary complications in AL patients are due to concurrent medical problems, such 
as bacteremia, sepsis, fungal infection or CHF. These patients also show an increased risk of 
thromboembolic disorders. Therefore, the occurrence of acute respiratory insufficiency in 
AL may be suspicious of pulmonary thromboembolism, especially if treatment with L-
asparaginase was previously implemented. L-asparaginase reduces antithrombin III levels 
thereby increasing the risk for thrombosis, which may be safely prevented with the use of 
heparin (Meister et al., 2008). 
Other chemotherapy drugs such as all-trans-retinoic acid (ATRA), imatinib and ara-C can 
cause a capillary leak syndrome which manifests as pulmonary edema, pleural effusions, 
pericardial effusions or ascites. Drug withdrawal and steroid therapy is generally 
recommended in this case (Meadors et al., 2006). 
7.1 The Acute Promyelocytic Leukemia Differentiation Syndrome 
All-trans retinoic acid (ATRA) and arsenic trioxide are agents used for the treatment of the 
acute promyelocytic leukemia (APL) with a unique toxicity profile. The APL Differentiation 
Syndrome or Retinoic Acid Syndrome is mediated by endothelial inflammation and vascular leak 
that occurs when leukemic blasts suddenly differentiate into mature granulocytes and adhere 
to pulmonary endothelium. The differentiation syndrome occurs in approximately 25% of 
patients with APL treated with these agents (Luesink et al., 2009; Montesinos et al., 2009). 
Diagnosis should be suspected clinically in the presence of dyspnea, unexplained fever, 
weight gain, peripheral edema, unexplained hypotension, acute renal failure or CHF, but 
particularly by a chest radiograph demonstrating interstitial pulmonary infiltrates or pleuro-
pericardial effusion. In this situation, dexamethasone should be started promptly and ATRA 
temporarily discontinued if the patient develops respiratory distress or renal failure. 
Prophylactic treatment with corticosteroids is recommended in patients with a WBC count 
greater than 5 x 109/l to reduce mortality and morbility (Sanz et al., 2009). 
8. Cutaneous toxicity 
Cutaneous side effects related to chemotherapy (Table 6) may range from relatively 
common adverse events, such as alopecia or hyperpigmentation (which are the result of 
direct toxicity on skin in contact with the drugs through blood or sweat) to more unusual 
phenomena such as photosensitivity or hypersensitivity reactions (DeSpain, 1992). 
Most chemotherapeutic agents may cause alopecia. Hair loss usually begins 7 to 10 days 
after the initiation of treatment and is prominent within 1 to 2 months of treatment. Once 
chemotherapy is finished hair grows back in the majority of the patients, although it may 
present a different texture or color. 
Pigmentary changes involving the skin, nails, and mucous membranes are usually related to 
alkylating agents and antitumor antibiotics, but they may as well occur with other drugs 
used in AL, namely etoposide, MTX or vincristine. The latter may cause a distinctive pattern 
of hyperpigmentation called Serpentine Hyperpigmentation, which follows an underlying vein 
proximal to an infusion site (Payne, A.S. et al., 2006). 
Eccrine Squamous Syringometaplasia is characterized by self-limited, asymptomatic erythematous 
papules on trunk and extremities that may be confused with erythema nodosum. 
MTX can produce a phototoxic recall reaction (Photoreactivation) in the absence of light. It is 
characterized by an erythematous eruption in the distribution of UV-induced sunburns that 
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may have occurred months or years prior to the administration of the drug. HD-MTX is also 
associated with severe erythema in sun-exposed areas when the drug is given within two to 
five days of exposure to UV light. In contrast to Photoreactivation, retreatment with MTX 
does not usually reproduce the reaction (Payne, A.S., DMF, 2011). Patients receiving 
photosensitizing drugs should be counseled regarding the risk of adverse reactions to 
sunlight and encouraged to use UV protection with sunscreens and protective clothing. 
 
Agent AL CP ESS PS AE NEH SS HR 
Alkylating agents +        
Cyclophosphamide + + +   +  + 
Ifosfamide +        
Antimetabolites         
Cytarabine +  +  ++ ++  + 
6-mercaptopurine     +    
Methotrexate + + + + +   + 
Antibiotics         
Doxorubicin +  +  + +  + 
Plant alkaloids         
Vincristine and Vinblastine* + +  +     
Etoposide +  +  +   ++ 
Tyrosine kinase inhibitors         
Imatinib  +  +   +  
Miscellaneous         
L-asparaginase        ++ 
Tretinoin (ATRA)       +  
AL, Alopecia; CP, Cutaneous Hyper-Pigmentation; ESS, Eccrine squamous syringometaplasia; PS, 
Photosensibility; AE, Acral erythema; NEH, Neutrophilic eccrine hidradenitis ; SS, Sweet´s Syndrome; 
HR, Hypersensitivity reactions. 
Table 6. Cutaneous toxicity of the main chemotherapy agents used in AL. 
Acral Erythema or Hand-Foot Syndrome, is characterized by painful erythematous plaques on 
the palms and soles and heals with prominent desquamation that usually resolves within 
two to four weeks after discontinuation of the causative agent (Figure 4). 
 
 
Fig. 4. Hand-Foot Syndrome in a child treated with ara-C for AL 
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Neutrophilic Eccrine Hidradenitis (NEH) is a reactive disorder that may occur in association 
with malignancy (with or without chemotherapy), infections, and certain medications. NEH 
is characterized by asymptomatic and self-limited violaceus plaques on the trunk and 
extremities. In all cases of suspected NEH, a biopsy should be performed to differentiate of 
septic emboli, metastatic infiltrates or Sweet´s Syndrome (Brehler et al., 1997). 
Sweet´s Syndrome (SS), also called Acute Febrile Neutrophilic Dermatosis, is characterized by 
fever, neutrophilia, erythematous and painful skin lesions, diffuse neutrophilic infiltrate in 
the dermis, and rapid response to corticosteroids (Saavedra et al., 2006). Ten to twenty per 
cent of SS cases are related to neoplasms, especially AML, the remaining being idiopathic o 
drug related. In AL patients, therapy with cytokines such as granulocyte colony-stimulating 
factor (G-CSF) and all-trans retinoic acid (ATRA) are involved in most cases (Thompson & 
Montarella, 2007) (Figure 5). 
 
 
Fig. 5. Sweet Syndrome in an adult patient treated with ATRA for APL 
Hypersensitivity reactions (HR) typically occur within an hour of drug administration and 
are characterized by pruritus, urticaria, swelling at the injection site, rash and in more severe 
cases, bronchospasm and hypotension. L-Asparaginase shows the highest risk for such 
reactions. The overall risk approaches 30% after four doses, but it can be also observed after 
the first dose. Some risk factors for this reaction are IV administration, prior exposure to L-
Asparaginase and weekly intervals of administration (as opposed to daily). 
There is no reliable method for determining who will sustain a HR with this drug. Skin 
testing is not worthwhile for this purpose. Changing to intramuscular Erwinia L-
asparaginase instead of E.Coli L-asparaginase or use modified asparaginase with attached 
polyethylene glycol are suitable options for sensitized patients (Earl, 2009). Etopoxide is 
also capable of producing HR in 6-7% of patients from the first dose, especially when the 
drug is infused. Recommended anaphylaxis precautions for patients receiving these drugs 
include: blood pressure monitoring, premedication with IV diphenhydramine and having 
an IV access to administer epinephrine and corticosteroids in case of reaction (Shepherd, 
2003). 
Ara-C causes an acute reaction called the Cytarabine Syndrome characterized by high fever, 
rigors, diaphoresis, myalgia, arthralgia, conjunctivitis and maculopapular rash. This ara-C 
syndrome may not be a HR but a constellation of direct toxicities of the drug which is likely 
mediated by cytokines. Corticosteroids are the treatment of choice for this syndrome (Chng, 
2003). 
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9. Pharmacogenetics determinants of chemotherapy toxicity in Acute 
Leukemia 
The fact that the efficacy of chemotherapy in AL patients has significantly increased in the 
last twenty years, has rendered a growing body of pharmacogenetic studies focused on 
toxicity rather than efficiency of chemotherapy drugs. Indeed, some genetic polymorphisms 
have been identified to play an important role. 
Most notably, polymorphisms in the thiopurine methyltransferase (TPMT) gene, which 
codes for a key enzyme in the metabolism of 6-MP, have been shown to produce a 
defective enzyme. Individuals homozygous for these SNPs present extremely high levels 
of active thioguanine nucleotides and therefore may have unacceptable, life-threatening 
toxicity from normal doses of 6-MP. In consequence, AL patients scheduled to receive 6-
MP are regularly tested for polymorphisms in the TPMT gene in order to adjust therapy 
(Relling et al., 1999). 
MTX, the cornerstone for therapy of ALL, has also been the focus of many pharmacogenetic 
studies aimed to identify genetic determinants of its toxicity. The methylenetetrahydrofolate 
reductase (MTHFR) gene has been by far the most extensively studied. Two polymorphisms, 
C677T and A1298C, have been associated with increased MTX toxicity, with the first likely 
playing a more significant role (Gervasini, 2009). Accordingly, some ALL treatment 
protocols in the induction phase include MTX dose reductions for subjects homozygous for 
the 677T variant or for those carrying both heterozygous genotypes (Badell et al., 2008). 
Given the complexity of the MTX mechanism of action, there are possibly polymorphisms in 
genes other than MTHFR that could be involved in the development of MTX adverse effects. 
Particularly, the occurrence of polymorphisms in membrane transporters that are responsible 
for the intake and efflux of MTX may constitute an exciting field of research (Gervasini, 2009). 
There are other drugs included in the chemotherapy of AL whose toxicity may also be 
increased by the presence of genetic polymorphisms. In this regard, some studies have 
addressed the impact of polymorphisms in ATP binding cassette (ABC) transporters on the 
toxicity of imatinib, vincristine or mitoxantrone, albeit with contradictory results (Cotte et 
al., 2009; Gurney et al., 2007; Hartman et al., 2010; Plasschaert et al., 2004). In addition, 
polymorphisms in drug-metabolizing enzymes such cytochrome P450 (CYP) 2B6 or CYP2D6 
may also be involved in the occurrence of adverse effects in response to treatments including 
imatinib, cyclophosphamide and etoposide (Gardner et al., 2006; Kishi et al., 2004; Rocha et al., 
2009). However, these results are far from being consistently demonstrated and further 
studies are needed to elucidate whether these polymorphisms represent a clinical concern. 
10. Conclusions 
In this chapter we have aimed to describe a number of guidelines to correctly recognize and 
treat the main adverse effects induced by chemotherapy in AL patients. In order to identify 
subjects at higher risk of toxicity, a complete clinical-analytical evaluation must be performed 
in all patients before the administration of each chemotherapy cycle. Furthermore, clinicians 
should be familiar with the different metabolic pathways of each administered drug, and 
doses should be adjusted accordingly if necessary, especially in cases with decreased renal or 
liver function. However, even with these precautions, chemotherapy-induced toxicity is still 
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an important clinical concern in AL. Indeed, at the present time the cornerstone of therapy for 
AL is still formed by a reduced number of drugs with a highly toxic profile. 
The present challenge would therefore be to reduce the frequency and seriousness of 
adverse effects while maintaining efficacy and avoiding overtreatment of patients. The 
design of new drugs such as the so-called molecular target drugs, the further development 
of existing therapeutic groups, or the knowledge of genetic determinants of toxicity may 
help achieve these goals.  
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